Conference Committee

Tomas Cihlar, Gilead Sciences, USA

Tomas Cihlar is a Senior Director of Biology at Gilead. After receiving PhD in Biochemistry from IOCB in Prague, Czech Republic in 1994, he jointed Gilead as a postdoctoral fellow. In subsequent years, he focused on the pharmacology of antiviral nucleotide analogs and supported the preclinical and clinical development of several Gilead’s products including Viread, Hepsera, and Vistide. Tomas Cihlar is currently responsible for coordinating virology and viral immunology research at Gilead including programs for the cure of chronic viral infections. He co-invented GS-7340, a novel form of tenofovir currently in clinical development and led a team that identified a novel nucleotide HIV RT inhibitor GS-9131. In 2006, he received William Prusoff Young Investigator Award from the International Society of Antiviral Research for his work on antiviral nucleotide analogs.

« Go Back